Developer of small molecule drugs designed to treat metabolic disorders and cancer. The company's drugs target the master regulatory switch for fat production, known as sterol regulatory element-binding proteins (SREBP), enabling physicians to treat obesity, non-alcoholic fatty liver disease, type II diabetes, and lipid disorders.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Later Stage VC | 19-May-2018 | $2.08M | 00.000 | Completed | Generating Revenue | |
3. Early Stage VC (Series A) | 18-Mar-2016 | 000 | 000 | 0000 | Completed | Generating Revenue |
2. Angel (individual) | 06-Nov-2015 | Cancelled | Generating Revenue | |||
1. Grant | 01-Jan-2014 | $1.84M | Completed | Generating Revenue |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 000,000 | 00.000000 | 000 | 000 | 00 | 000 | 00.000 |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3510027-A1 | Di-substituted pyrazole compounds for the treatment of diseases | Pending | 07-Sep-2016 | 0000000000 | |
JP-2019530742-A | Disubstituted pyrazole compounds for the treatment of diseases | Pending | 07-Sep-2016 | 0000000000 | |
AU-2017323521-A1 | Di-substituted pyrazole compounds for the treatment of diseases | Granted | 07-Sep-2016 | 0000000000 | |
US-20190194167-A1 | Di-substituted pyrazole compounds for the treatment of diseases | Pending | 07-Sep-2016 | 0000000000 | 0 |
CA-3036195-A1 | Di-substituted pyrazole compounds for the treatment of diseases | Pending | 07-Sep-2016 | C07D401/14 |
Name | Representing | Role | Since |
---|---|---|---|
Adam Kuspa | FGH BioTech | Board Member | 000 0000 |
Joe Wakil | FGH BioTech | President & Board Member | 000 0000 |
Salih Wakil Ph.D | FGH BioTech | Co-Founder, President & Chairman | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
BCM Technologies | Venture Capital | Minority | 000 0000 | 000000 0 | |
U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 |